2023年5月23日

全球肿瘤浸润淋巴细胞市场预计将从81.2亿年的2022美元增长到93.1亿年的2023美元,复合年增长率(CAGR)的14.5%。肿瘤浸润淋巴细胞市场预计将增长到155.6亿年的2027美元的CAGR为13.7%。越来越多的癌症患者有望推动增长的肿瘤浸润的淋巴细胞(直到)市场。癌症是一种疾病,一些细胞在体内发展失控,扩散到身体的其他地区,导致一系列健康问题,其中一些可能是致命的。肿瘤浸润淋巴细胞是一种免疫细胞,可以检测和摧毁癌细胞。肿瘤浸润淋巴细胞提取患者的肿瘤种植大量的外部实验室之前输回患者协助免疫系统杀死癌细胞。例如,2022年1月,美国癌症协会称,美国志愿者卫生组织致力于癌症,在2022年,有1918030新的预测癌症病例和609360人死亡。而在2020年,有1806590新的预测癌症病例和606520人死亡。因此,癌症患者的增加将推动肿瘤淋巴细胞渗透市场。技术进步是一个关键的趋势在肿瘤浸润淋巴细胞市场越来越受欢迎。 Major companies operating in the tumor-infiltrating lymphocytes market are focused on developing technologically advanced solutions to strengthen their position in the market. For instance, in May 2022, Obsidian Therapeutics Inc., a US-based biotechnology firm that develops engineered tumor-infiltrating lymphocytes (TIL cells) and gene treatments, announced the release of cytoDRIVE technology. The new technology's data shows how to precisely regulate the time and level of protein activity using FDA-approved small chemicals. Using powerful cytokines like IL12 to support cell treatments, is a potential technique for treating solid cancers. The findings show that numerous cytokines, including IL12, IL23, IL2, and IFN, may be regulated robustly and reversibly, possibly allowing for their safe usage in adoptive cell therapy applications. In January 2021, Turnstone Biologics Corporation, a US-based diagnostic biotechnology firm that is pioneering the development of cancer immunotherapies, acquired Myst Therapeutics Inc. for an undisclosed amount. This acquisition provides Turnstone Biologics Corp. with full rights to Myst Therapeutics Inc.'s technology, complete R&D resources, current development partnerships, and a portfolio of tumor-infiltrating lymphocytes (TIL) projects. Myst Therapeutics Inc. is a US-based biotechnology company that focuses on the development of cancer immunotherapies employing tumor-infiltrating lymphocytes (TIL) and the development of novel T-cell therapeutics for solid tumors. North America was the largest region in the tumor infiltrating lymphocytes market in 2022. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Description: Where is the largest and fastest growing market for tumor infiltrating lymphocytes? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tumor infiltrating lymphocytes market global report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. Scope